Brand against brand · semaglutide and liraglutide
Ozempic vs Victoza
From the two FDA labels, read Published by PepVault
Ozempic is semaglutide, a GLP-1 receptor agonist, from Novo Nordisk; Victoza is liraglutide, a GLP-1 receptor agonist, from Novo Nordisk.
FDA approved Ozempic for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Victoza is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes and heart disease.
Label against label
| Compared | Ozempic | Victoza |
|---|---|---|
| Active ingredient | semaglutide | liraglutide |
| Class | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Maker | Novo Nordisk | Novo Nordisk |
| Approved for | Type 2 diabetes; heart and kidney risk in type 2 diabetes | Type 2 diabetes (adults and children 10 and up); heart risk |
| Forms | Multi-dose pen; Single-dose prefilled syringe; Tablet | Prefilled pen |
| How often | once a week or once a day | once a day |
| Starting dose | 0.25 mg a week (injection); 1.5 mg a day (tablets) | 0.6 mg a day |
| Top dose on the label | 2 mg a week (injection); 9 mg a day (tablets) | 1.8 mg a day |
| Most reported side effect | Nausea, 20.3% on 1 mg (placebo 6.1%) | Nausea, 20% on 1.8 mg (placebo 5%) |
| Boxed warning | “RISK OF THYROID C-CELL TUMORS” | “RISK OF THYROID C-CELL TUMORS” |
| First approved | 2017 | 2010 |
Each label’s side-effect figure comes from its own trials, at its own doses and in its own patients; as the labels themselves say, rates from different trials can’t be compared directly.
The two dosing schedules
This is the dosing schedule as the FDA label states it. A prescriber sets the actual dose and when it changes; it is not an instruction to the reader.
Ozempic injection, once a week
Ozempic tablets, once a day
Victoza, once a day (adults)

A missed dose, on each label
The trial evidence
Questions
What is the difference between Ozempic and Victoza?
Ozempic is semaglutide, a GLP-1 receptor agonist; Victoza is liraglutide, a GLP-1 receptor agonist. Their labels approve them for different uses and set different schedules.
What are Ozempic and Victoza approved for?
Ozempic is approved for blood sugar control in adults with type 2 diabetes, and lowering heart and kidney risks in some of them. Victoza is approved for blood sugar control in type 2 diabetes from age 10, and lowering heart risk in adults with type 2 diabetes and heart disease.
How often are Ozempic and Victoza taken?
Ozempic is taken once a week or once a day, as an injection or a tablet; Victoza once a day, as an injection.
What are the dose ranges of Ozempic and Victoza?
On their labels, Ozempic runs 0.25 mg to 2 mg once a week or 1.5 mg to 9 mg once a day, and Victoza 0.6 mg to 1.8 mg once a day. A prescriber sets the actual dose.
What is the most common side effect of Ozempic and Victoza?
On Ozempic’s label: nausea, 20.3% on 1 mg (placebo 6.1%). On Victoza’s: nausea, 20% on 1.8 mg (placebo 5%).
Sources
- OZEMPIC (semaglutide) injection, for subcutaneous use, FDA label on DailyMed (version 20, published Jun 10, 2026; read Nov 18, 2026)
- RYBELSUS (semaglutide) tablets and OZEMPIC (semaglutide) tablets, for oral use, FDA label on DailyMed (version 14, published Aug 19, 2026; read Nov 18, 2026)
- VICTOZA (liraglutide) injection, for subcutaneous use, FDA label on DailyMed (version 31, published Nov 17, 2025; read Nov 18, 2026)
- Drugs@FDA, NDA 209637 (Ozempic, the injection; application first approved 2017)
- Drugs@FDA, NDA 213051 (Ozempic, the tablets, added to the application by supplement 30 on Jan 30, 2026; application first approved 2019)
- Drugs@FDA, NDA 022341 (Victoza, the injection; application first approved 2010)
PepVault is not affiliated with Novo Nordisk. Ozempic is a trademark of its owner. Victoza is a trademark of its owner.